Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344682 · ClinicalTrials.gov registry record · Phase 4
Memantine Augmentation of Antidepressants
A Phase 4 study of Depressive Disorder, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00344682: Completed Phase 4 study of Depressive Disorder, sponsored by University of Massachusetts, Worcester.
NCT00344682 is a Phase 4 study of Depressive Disorder that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 31 participants, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00344682, a Phase 4 study of Depressive Disorder, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.
Primary Outcome
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG memantine
Study Locations (1)
Massachusetts
- Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School) - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT00344682 record still lists
NCT00344682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00344682 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00344682 about?
NCT00344682 is a clinical study titled "Memantine Augmentation of Antidepressants". This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.
What is the current status of trial NCT00344682?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2006-06. Estimated completion is 2011-12.
What conditions does trial NCT00344682 study?
This clinical trial studies the following conditions: Depressive Disorder.
What interventions are being tested in trial NCT00344682?
The interventions under investigation include: Placebo (DRUG), memantine (DRUG).
Who is sponsoring clinical trial NCT00344682?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00344682 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00344682's enrollment target sits among peer trials
31 43rd of 47 higher than 5 of 47 other Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Electroconvulsive Therapy for Depression
COMPLETED · Phase 4
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
Measurement-Based Care (MBC) Implementation, Effectiveness, and Mechanisms of Change
RECRUITING · NA
-
Research Evaluating Vagal Excitation AND Anatomical Links
RECRUITING · NA
-
Unified Protocol: Community Connections
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia